3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
13
NET
2
Endocrine
2
Tumor-Agnostic
1
Sarcoma
1
Gynecologic
1
Conditions
Neuroendocrine Tumors
2
Interventions
lutetium Lu 177 dotatate
32
Everolimus
19
Magnetic Resonance Spectroscopy
14
gallium Ga 68 dotatate
12
Temozolomide
12
Nivolumab
11
Capecitabine
10
pembrolizumab
9
lanreotide
9
cabozantinib
8
Positron Emission Tomography Computed Tomography
8
177Lu-octreotide, DOTA(0)-Tyr(3)-
8
Ga(III)-DOTATOC
7
3-Iodobenzylguanidine
7
Somatostatin
6
Octreotide
6
Lutetium-177
6
Carboplatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
telotristat ethyl
5
surufatinib
5
lenvatinib
5
Ipilimumab
5
Fluorodeoxyglucose F18
5
pasireotide
4
copper dotatate CU-64
4
avelumab
4
Single Photon Emission Computed Tomography Computed Tomography
4
Positron-Emission Tomography
4
Bevacizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Yttrium-90
×
NET
×
Clear all
NCT04339036
2026-06-04
CapTemY90
Abramson Cancer Center at Penn Medicine
Phase 2
Recruiting
70 enrolled
NCT04790708
2021-03-10
FENET-2016
University Hospital of Ferrara
Phase NA
Unknown
250 enrolled